Choosing a VMAT2 Inhibitor for Huntington’s Chorea When the Whole Class Carries a Suicidality Warning
Three drugs, one shared mechanism, and one shared warning that carries different weight in Huntington’s disease than in almost any other condition.
Marcus W., 44, has run the same CNC lathe at a precision-parts machine shop for nineteen years, work that requires him to keep both hands still and exactly where he expects them to be around spinning metal. He watched his mother die of Huntington’s disease six years ago, a decline he now recognizes symptom by symptom in his own body since testing positive for the expanded CAG repeat three years ago, following her diagnosis, at his own request. His chorea — involuntary, dance-like movements that started subtly in his fingers and has progressively spread to his arms and trunk — has gone from something he could mostly hide from coworkers to something his supervisor has now raised directly, twice, as a safety concern around the machinery. He is not currently on any medication for the movements themselves, having managed until recently on reassurance and adaptation alone.
The three drugs available to treat HD chorea specifically all work the same way, depleting presynaptic dopamine, norepinephrine, and serotonin by inhibiting the vesicular monoamine transporter type 2, and all three carry the same boxed warning: increased risk of depression and suicidality, written into the class specifically because of what was observed in the trials that established each drug’s efficacy. That warning lands differently in Huntington’s disease than it would in almost any other condition, because HD itself independently and substantially raises suicide risk across the course of the illness, driven by the disease’s own neuropsychiatric burden as much as by the weight of watching a parent’s decline play out in real time, as Marcus has. He has not endorsed current suicidal ideation on today’s screen, and describes his mood as ‘about what you’d expect, nothing new,’ but a formal depression history has never actually been taken — the chorea, until now, was always the more visible problem.
Tetrabenazine has the longest track record and lowest cost but is dosed three times daily and metabolized partly through CYP2D6, producing wide interpatient variability in drug exposure and a real burden of sedation and parkinsonism at higher doses. Deutetrabenazine, a deuterium-substituted version of the same molecule, clears more slowly, allowing twice-daily dosing and, in its own pivotal trial data, less reported depression than tetrabenazine’s historical rate — though the comparison isn’t head-to-head. Valbenazine, approved specifically for HD chorea via the KINECT-HD trial, is dosed once daily and showed a real, statistically significant reduction in chorea severity against placebo. None of the three has been shown to be safer than the others on the outcome everyone in the room is most worried about.
Clinic, first visit for chorea treatment
His chorea is now a documented, twice-flagged occupational safety issue, and KINECT-HD showed a real, statistically significant reduction in chorea severity with valbenazine against placebo, dosed once daily — genuinely practical for a working patient on a demanding schedule. I'd start it today.
The occupational safety concern is real, and I'm not suggesting we ignore it. But every VMAT2 inhibitor carries the same boxed warning — increased depression and suicidality — and Huntington's disease independently raises suicide risk across the course of the illness on its own. Marcus watched his mother die of this disease, and nobody has ever taken a formal depression history from him. Today's screen being negative for active ideation isn't the same as having a real baseline.
Starting the drug before we have that baseline means that if his mood does shift in a month, we won't be able to tell whether it's the medication, the disease's own progression, or grief we never actually assessed for — and by then it's a much harder question to untangle.
I don't think this has to be sequential. A structured psychiatric baseline can be completed today, in this same visit, rather than deferred to a future referral — and I'd start treatment today as well, given the real, current safety risk his chorea poses. Between the three agents, I'd lean toward deutetrabenazine for the twice-daily dosing and its trial data's somewhat lower reported depression rate, pending confirmation of his insurance coverage, with tetrabenazine and valbenazine both documented as reasonable alternatives if cost or tolerability push differently.
Agreed: same-day structured psychiatric baseline assessment, start deutetrabenazine today given the immediate occupational safety concern, a 2-week mood follow-up call rather than waiting for his next scheduled visit, and a parallel referral to HD-specific counseling.
Not agreed: whether deutetrabenazine was really the right first agent given cost is still unconfirmed, or whether tetrabenazine's lower cost should have taken priority given real uncertainty about his insurance coverage — left open pending a call from the clinic's pharmacy-access coordinator, not resolved at the visit itself.